Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer

10.1093/annonc/mdy245

Saved in:

Bibliographic Details
Main Authors:	Basu, B, Krebs, MG, Sundar, R, Wilson, RH, Spicer, J, Jones, R, Brada, M, Talbot, DC, Steele, N, Garces, AH Ingles, Brugger, W, Harrington, EA, Evans, J, Hall, E, Tovey, H, de Oliveira, FM, Carreira, S, Swales, K, Ruddle, R, Raynaud, FI, Purchase, B, Dawes, JC, Parmar, M, Turner, AJ, Tunariu, N, Banerjee, S, de Bono, JS, Banerji, U
Other Authors:	MEDICINE
Published:	OXFORD UNIV PRESS 2021
Subjects:	phase 1 m-TORC1/m-TORC2 inhibitor combination therapy ovarian cancer squamous non-small-cell lung cancer
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/206997
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-206997
record_format	dspace
spelling	sg-nus-scholar.10635-2069972021-11-24T11:11:58Z Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer Basu, B Krebs, MG Sundar, R Wilson, RH Spicer, J Jones, R Brada, M Talbot, DC Steele, N Garces, AH Ingles Brugger, W Harrington, EA Evans, J Hall, E Tovey, H de Oliveira, FM Carreira, S Swales, K Ruddle, R Raynaud, FI Purchase, B Dawes, JC Parmar, M Turner, AJ Tunariu, N Banerjee, S de Bono, JS Banerji, U MEDICINE phase 1 m-TORC1/m-TORC2 inhibitor combination therapy ovarian cancer squamous non-small-cell lung cancer 10.1093/annonc/mdy245 ANNALS OF ONCOLOGY 29 9 1918-1925 2021-11-22T06:39:29Z 2021-11-22T06:39:29Z 2018-09-01 2021-11-16T10:41:27Z Basu, B, Krebs, MG, Sundar, R, Wilson, RH, Spicer, J, Jones, R, Brada, M, Talbot, DC, Steele, N, Garces, AH Ingles, Brugger, W, Harrington, EA, Evans, J, Hall, E, Tovey, H, de Oliveira, FM, Carreira, S, Swales, K, Ruddle, R, Raynaud, FI, Purchase, B, Dawes, JC, Parmar, M, Turner, AJ, Tunariu, N, Banerjee, S, de Bono, JS, Banerji, U (2018-09-01). Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. ANNALS OF ONCOLOGY 29 (9) : 1918-1925. ScholarBank@NUS Repository. https://doi.org/10.1093/annonc/mdy245 09237534 15698041 https://scholarbank.nus.edu.sg/handle/10635/206997 OXFORD UNIV PRESS Elements
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	phase 1 m-TORC1/m-TORC2 inhibitor combination therapy ovarian cancer squamous non-small-cell lung cancer
spellingShingle	phase 1 m-TORC1/m-TORC2 inhibitor combination therapy ovarian cancer squamous non-small-cell lung cancer Basu, B Krebs, MG Sundar, R Wilson, RH Spicer, J Jones, R Brada, M Talbot, DC Steele, N Garces, AH Ingles Brugger, W Harrington, EA Evans, J Hall, E Tovey, H de Oliveira, FM Carreira, S Swales, K Ruddle, R Raynaud, FI Purchase, B Dawes, JC Parmar, M Turner, AJ Tunariu, N Banerjee, S de Bono, JS Banerji, U Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer
description	10.1093/annonc/mdy245
author2	MEDICINE
author_facet	MEDICINE Basu, B Krebs, MG Sundar, R Wilson, RH Spicer, J Jones, R Brada, M Talbot, DC Steele, N Garces, AH Ingles Brugger, W Harrington, EA Evans, J Hall, E Tovey, H de Oliveira, FM Carreira, S Swales, K Ruddle, R Raynaud, FI Purchase, B Dawes, JC Parmar, M Turner, AJ Tunariu, N Banerjee, S de Bono, JS Banerji, U
author	Basu, B Krebs, MG Sundar, R Wilson, RH Spicer, J Jones, R Brada, M Talbot, DC Steele, N Garces, AH Ingles Brugger, W Harrington, EA Evans, J Hall, E Tovey, H de Oliveira, FM Carreira, S Swales, K Ruddle, R Raynaud, FI Purchase, B Dawes, JC Parmar, M Turner, AJ Tunariu, N Banerjee, S de Bono, JS Banerji, U
author_sort	Basu, B
title	Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer
title_short	Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer
title_full	Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer
title_fullStr	Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer
title_full_unstemmed	Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer
title_sort	vistusertib (dual m-torc1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer
publisher	OXFORD UNIV PRESS
publishDate	2021
url	https://scholarbank.nus.edu.sg/handle/10635/206997
_version_	1718367925370355712

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer

Similar Items